Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): where Y is H or F, with a single overall linker moiety connecting two topoisomerase inhibitor derivatives to a Ligand Unit, wherein the topoisomerase inhibitor derivatives are cleavable from the Ligand Unit. Also provided is A* with the linking unit attached, and intermediates for their synthesis.

Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.

Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.

Abstract: A compound of formula IV: as well as drug-linkers and conjugates comprising this compound, and the use of the conjugates in treating cancer.

Abstract: A method of synthesising a compound of formula (I) from a compound of formula (II) wherein R2 is phenyl, substituted at either the meta- or para-position by the group (III) where Q is an amino acid residue (—C(?O)—X1—NH—), a di-amino acid residue (—C(?O)—X1—X2—NH—) or a tri-amino acid residue (—C(?O)—X1—X2—X3—NH—); ProtN3 is an amino protecting group; R2pre is phenyl, substituted at the same position as R2 by —NH2; comprising reacting a compound of formula (II) with a compound of formula (IV) in the presence of HATU in dichloromethane or chloroform or a mixture thereof.

Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.

Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.

Abstract: A conjugate of formula I, wherein Ab is a modified antibody having at least one free conjugation site on each heavy chain.

Abstract: A conjugate of formula (I): L-(DL)p, wherein L is a Ligand unit, D is a Drug Linker unit of formula (II), wherein p is an integer of from 1 to 20.

Abstract: A conjugate of formula (I):L-(DL)p, wherein L is a Ligand unit, D is a Drug Linker unit of formula IIa, IIb or IIc, wherein p is an integer of from 1 to 20.

Abstract: A compound with the formula I, wherein R2 is of formula II, where A is a C5-7 aryl group, X is selected from the group consisting of: OH, SH, CO2H, COH, N?C?O, NHNH2, CONHNH2, (III), (IV), and NHRN, wherein RN is selected from H and C1-4 alkyl, and either: (i) Q1 is a single bond, and Q2 is selected from a single bond and —Z—(CH2)n—, where Z is selected from a single bond, O, S and NH and n is from 1 to 3; or (ii) Q1 is —CH?CH—, and Q2 is a single bond; and its conjugates.

Abstract: A conjugate of formula (I): L-(DL)p, wherein L is a Ligand unit, D is a Drug Linker unit of formula (II), wherein p is an integer of from 1 to 20.

Abstract: A compound with the formula I, wherein R2 is of formula II, where A is a C5-7 aryl group, X is selected from the group consisting of: OH, SH, CO2H, COH, N?C?O, NHNH2, CONHNH2, (III), (IV), and NHRN, wherein RN is selected from H and C1-4 alkyl, and either: (i) Q1 is a single bond, and Q2 is selected from a single bond and —Z—(CH2)n—, where Z is selected from a single bond, O, S and NH and n is from 1 to 3; or (ii) Q1 is —CH?CH—, and Q2 is a single bond; and its conjugates.

Abstract: A compound which is selected from A: and salts and solvates thereof.

Abstract: A compound which is selected from A: and salts and solvates thereof.